Editorial Policy
Effective date: August 2, 2026
This policy describes how sofidex selects, writes, reviews, publishes, corrects, and retires clinical content.
sofidex publishes only claims about its process that it can support with its own records. Where a practice is not yet in place, this policy says so rather than describing an aspiration.
1. Scope and current coverage
sofidex is a clinical reference for qualified healthcare professionals. Its intended scope is a fixed, published topic taxonomy covering seventeen specialties.
Not all of that scope is written. Only the specialties shown as available in the library have published articles; the remainder are marked as forthcoming and contain nothing. A specialty is not made available until its articles are written and reviewed. Do not infer from the presence of the taxonomy that a topic has been covered — if you cannot find an article, assume it has not been written rather than that the topic was considered and dismissed.
2. Editorial independence
sofidex accepts no sponsored content and no payment to include, exclude, or shape a topic. Nobody may buy a mention, a ranking, or a favourable line, and there is no sponsored material to label.
sofidex intends to carry advertising, and it is kept structurally separate from the writing. Advertisements are chosen by the network from the content of a page; no advertiser sees a draft, chooses a topic, or is told what is coming. The people who write the articles have no contact with the people who sell the space, and an advertisement can never appear on the emergency pages, the patient support pages or the clinician side. If that separation is ever unclear on a page, it is a bug — say so, using the contact address below.
Some links to products carry a commission. Where an article mentions something a reader can buy — an exercise mat, a sunscreen, a supplement, an over-the-counter cream — the link to buy it may earn sofidex a commission, and every page carrying one says so above the article. It changes nothing about what is written: the product is named because the article is about it, the link is added afterwards, and no product, brand or seller is chosen because it pays. A link is not an endorsement. Some linked products are ones the article itself says have weak evidence; the article says so in the same words either way, and the reader decides. Supplements and medicines are linked only when sold without a prescription, and never where the article warns against using them.
3. Topic selection and structure
Topics are drawn from a maintained taxonomy based on clinical importance, disease burden, variation in practice, and potential for harm. Each article states its specialty and organ system, and carries a publication date and a last-updated date.
Articles are structured into consistent sections so that the same kind of information appears in the same place across topics.
4. Authorship and review
Clinical content is produced with editorial oversight by or on behalf of sofidex, with the involvement of qualified clinicians in the editorial process. AI tools are used in drafting and editing; see the AI Disclosure. The extent of review varies with the material, and no representation is made that any particular item received any particular form or depth of review. AI is not credited as an author.
Ghost authorship and honorary authorship are prohibited. No person is represented as an author or reviewer unless that person completed the stated work and approved the published version.
sofidex does not currently operate a multi-reviewer editorial board or a published external peer-review process. If one is established, this section will be updated to describe it, and this paragraph removed.
5. Conflicts of interest
Contributors disclose financial and relevant non-financial relationships that could reasonably affect judgment, including employment, consulting, advisory roles, speaking fees, research support, equity, intellectual property, and paid expert work. Material conflicts may result in recusal, additional independent review, or exclusion.
6. Evidence
Sources may include peer-reviewed research, systematic reviews, clinical guidelines, regulatory communications, official drug labeling, and public-health authorities. Evidence is evaluated for study design, risk of bias, directness, consistency, precision, clinical relevance, and applicability.
sofidex distinguishes evidence from expert interpretation. Material uncertainty, disagreement, and evidence gaps are stated where they could affect a decision.
sofidex does not currently apply a formal grading framework such as GRADE, and does not display evidence-certainty grades. Recommendation wording is intended to reflect the strength of the underlying evidence, but it is not a graded output and should not be read as one.
7. Citations and originality
Where citations appear, they are intended to point the reader to a source they can consult themselves. Not every statement carries a citation. The presence or absence of a citation is not a representation that a given statement was, or was not, independently verified.
Contributors must submit original or properly licensed material. Plagiarism, fabricated data or citations, and undisclosed duplicate publication are prohibited.
8. Drug and interaction data
The interaction checker is a lookup against third-party reference data — the U.S. National Library of Medicine's RxNorm vocabulary and openFDA labeling — not editorial content written by sofidex. It is refreshed from those sources on a schedule. sofidex does not warrant that it identifies every interaction, and an empty result is not evidence that no interaction exists.
9. Updates, corrections, and version history
Every change to an article is recorded with its author and timestamp, and previous versions are retained and can be restored. An "updated" date reflects a substantive content change; cosmetic edits do not reset it.
Material errors are corrected promptly. Where an error could create immediate clinical risk, sofidex may withdraw or disable the article while it is reviewed. Where a URL changes, the previous address continues to resolve to the article rather than breaking.
sofidex does not currently operate a scheduled surveillance process that systematically re-reviews every published article at a fixed interval, and does not publish a review-interval commitment it cannot meet. Articles are revised when new evidence, regulatory action, or a reported error makes revision necessary.
10. Reporting an error
Report a suspected error to [email protected]. Include the article title, the URL, the date you accessed it, what you believe is wrong, and any supporting source. Reports are logged and investigated. Do not include patient-identifiable information.
11. Policy review
This policy is reviewed at least annually and after any material change to editorial process. The current version and effective date are published here.